Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects.
Identifieur interne : 003293 ( Main/Exploration ); précédent : 003292; suivant : 003294Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects.
Auteurs : RBID : pubmed:12690521English descriptors
- KwdEn :
- Adult, Aged, Antigen-Presenting Cells (immunology), Antigens, CD (metabolism), Antigens, Neoplasm (therapeutic use), Female, Granulocyte-Macrophage Colony-Stimulating Factor (metabolism), HLA-A2 Antigen (metabolism), Humans, Immunotherapy, Indium Radioisotopes (diagnostic use), Injections (methods), Intradermal Tests, Lymph Nodes (immunology), Lymph Nodes (radionuclide imaging), Macrophages (drug effects), Macrophages (physiology), Macrophages (radionuclide imaging), Male, Melanoma (radionuclide imaging), Melanoma (therapy), Middle Aged, Neoplasm Proteins (therapeutic use), Peptide Fragments, Receptors, CCR7, Receptors, Chemokine (metabolism), Skin Neoplasms (radionuclide imaging), Skin Neoplasms (therapy).
- MESH :
- chemical , diagnostic use : Indium Radioisotopes.
- chemical , metabolism : Antigens, CD, Granulocyte-Macrophage Colony-Stimulating Factor, HLA-A2 Antigen, Receptors, Chemokine.
- drug effects : Macrophages.
- immunology : Antigen-Presenting Cells, Lymph Nodes.
- methods : Injections.
- physiology : Macrophages.
- radionuclide imaging : Lymph Nodes, Macrophages, Melanoma, Skin Neoplasms.
- chemical , therapeutic use : Antigens, Neoplasm, Neoplasm Proteins.
- therapy : Melanoma, Skin Neoplasms.
- Adult, Aged, Female, Humans, Immunotherapy, Intradermal Tests, Male, Middle Aged, Peptide Fragments, Receptors, CCR7.
Abstract
Patients' autologous macrophages (AM) were used as antigen-presenting cells (APC) in a vaccination protocol against malignant melanoma. AM were administered by various routes, including intralymphatic, since these cells did not express CCR7, a molecule required for APC migration to lymph nodes. Seven HLA-A2 patients with metastatic melanoma-two classified as M1 and five as M3-were included in the study. AM were produced from leukapheresis-separated mononuclear cells by 7-day culture with granulocyte-macrophage colony-stimulating factor. After separation by elutriation, AM were frozen in aliquots and subsequently thawed at monthly intervals, exposed to MAGE-3(271-279) peptide and injected subcutaneously into lymph nodes or into one peripheral lymph vessel. Intradermal tests were performed before and after treatment to determine peptide reactivity. No acute toxicity was observed following injection. One M1 patient had a 7-mm induration intradermal reaction response and was stabilized for 64 weeks. The M3 patients did not show any immunological or clinical response. In 11 patients, the biodistribution of 111In-labeled AM was investigated. There was no clear evidence that AM injected intradermally or subcutaneously left the site of injection. After injection into a lymph vessel of the foot region, scintigraphs showed five to ten popliteal and inguinocrural lymph nodes. This appeared to be the most efficient way to administer rapidly and safely large amounts of peptide-loaded APC into lymph nodes.
DOI: 10.1007/s00262-003-0390-y
PubMed: 12690521
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects.</title><author><name sortKey="Lesimple, Thierry" uniqKey="Lesimple T">Thierry Lesimple</name><affiliation wicri:level="3"><nlm:affiliation>Centre Régional de Lutte Contre le Cancer Eugène Marquis, rue de la Bataille Flandres-Dunkerque, CD 44229, 35042 Rennes, France. lesimple@rennes.fnclcc.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Régional de Lutte Contre le Cancer Eugène Marquis, rue de la Bataille Flandres-Dunkerque, CD 44229, 35042 Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Moisan, Annick" uniqKey="Moisan A">Annick Moisan</name></author><author><name sortKey="Carsin, Andre" uniqKey="Carsin A">André Carsin</name></author><author><name sortKey="Ollivier, Isabelle" uniqKey="Ollivier I">Isabelle Ollivier</name></author><author><name sortKey="Mousseau, Mireille" uniqKey="Mousseau M">Mireille Mousseau</name></author><author><name sortKey="Meunier, Bernard" uniqKey="Meunier B">Bernard Meunier</name></author><author><name sortKey="Leberre, Claudine" uniqKey="Leberre C">Claudine Leberre</name></author><author><name sortKey="Collet, Brigitte" uniqKey="Collet B">Brigitte Collet</name></author><author><name sortKey="Quillien, Veronique" uniqKey="Quillien V">Véronique Quillien</name></author><author><name sortKey="Drenou, Bernard" uniqKey="Drenou B">Bernard Drenou</name></author><author><name sortKey="Lefeuvre Plesse, Claudia" uniqKey="Lefeuvre Plesse C">Claudia Lefeuvre-Plesse</name></author><author><name sortKey="Chevrant Breton, Jacqueline" uniqKey="Chevrant Breton J">Jacqueline Chevrant-Breton</name></author><author><name sortKey="Toujas, Louis" uniqKey="Toujas L">Louis Toujas</name></author></titleStmt><publicationStmt><date when="2003">2003</date><idno type="RBID">pubmed:12690521</idno><idno type="pmid">12690521</idno><idno type="doi">10.1007/s00262-003-0390-y</idno><idno type="wicri:Area/Main/Corpus">003519</idno><idno type="wicri:Area/Main/Curation">003519</idno><idno type="wicri:Area/Main/Exploration">003293</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antigen-Presenting Cells (immunology)</term><term>Antigens, CD (metabolism)</term><term>Antigens, Neoplasm (therapeutic use)</term><term>Female</term><term>Granulocyte-Macrophage Colony-Stimulating Factor (metabolism)</term><term>HLA-A2 Antigen (metabolism)</term><term>Humans</term><term>Immunotherapy</term><term>Indium Radioisotopes (diagnostic use)</term><term>Injections (methods)</term><term>Intradermal Tests</term><term>Lymph Nodes (immunology)</term><term>Lymph Nodes (radionuclide imaging)</term><term>Macrophages (drug effects)</term><term>Macrophages (physiology)</term><term>Macrophages (radionuclide imaging)</term><term>Male</term><term>Melanoma (radionuclide imaging)</term><term>Melanoma (therapy)</term><term>Middle Aged</term><term>Neoplasm Proteins (therapeutic use)</term><term>Peptide Fragments</term><term>Receptors, CCR7</term><term>Receptors, Chemokine (metabolism)</term><term>Skin Neoplasms (radionuclide imaging)</term><term>Skin Neoplasms (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antigens, CD</term><term>Granulocyte-Macrophage Colony-Stimulating Factor</term><term>HLA-A2 Antigen</term><term>Receptors, Chemokine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Macrophages</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antigen-Presenting Cells</term><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Injections</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Macrophages</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Lymph Nodes</term><term>Macrophages</term><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antigens, Neoplasm</term><term>Neoplasm Proteins</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Immunotherapy</term><term>Intradermal Tests</term><term>Male</term><term>Middle Aged</term><term>Peptide Fragments</term><term>Receptors, CCR7</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients' autologous macrophages (AM) were used as antigen-presenting cells (APC) in a vaccination protocol against malignant melanoma. AM were administered by various routes, including intralymphatic, since these cells did not express CCR7, a molecule required for APC migration to lymph nodes. Seven HLA-A2 patients with metastatic melanoma-two classified as M1 and five as M3-were included in the study. AM were produced from leukapheresis-separated mononuclear cells by 7-day culture with granulocyte-macrophage colony-stimulating factor. After separation by elutriation, AM were frozen in aliquots and subsequently thawed at monthly intervals, exposed to MAGE-3(271-279) peptide and injected subcutaneously into lymph nodes or into one peripheral lymph vessel. Intradermal tests were performed before and after treatment to determine peptide reactivity. No acute toxicity was observed following injection. One M1 patient had a 7-mm induration intradermal reaction response and was stabilized for 64 weeks. The M3 patients did not show any immunological or clinical response. In 11 patients, the biodistribution of 111In-labeled AM was investigated. There was no clear evidence that AM injected intradermally or subcutaneously left the site of injection. After injection into a lymph vessel of the foot region, scintigraphs showed five to ten popliteal and inguinocrural lymph nodes. This appeared to be the most efficient way to administer rapidly and safely large amounts of peptide-loaded APC into lymph nodes.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12690521</PMID><DateCreated><Year>2003</Year><Month>07</Month><Day>01</Day></DateCreated><DateCompleted><Year>2003</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0340-7004</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Cancer immunology, immunotherapy : CII</Title><ISOAbbreviation>Cancer Immunol. Immunother.</ISOAbbreviation></Journal><ArticleTitle>Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects.</ArticleTitle><Pagination><MedlinePgn>438-44</MedlinePgn></Pagination><Abstract><AbstractText>Patients' autologous macrophages (AM) were used as antigen-presenting cells (APC) in a vaccination protocol against malignant melanoma. AM were administered by various routes, including intralymphatic, since these cells did not express CCR7, a molecule required for APC migration to lymph nodes. Seven HLA-A2 patients with metastatic melanoma-two classified as M1 and five as M3-were included in the study. AM were produced from leukapheresis-separated mononuclear cells by 7-day culture with granulocyte-macrophage colony-stimulating factor. After separation by elutriation, AM were frozen in aliquots and subsequently thawed at monthly intervals, exposed to MAGE-3(271-279) peptide and injected subcutaneously into lymph nodes or into one peripheral lymph vessel. Intradermal tests were performed before and after treatment to determine peptide reactivity. No acute toxicity was observed following injection. One M1 patient had a 7-mm induration intradermal reaction response and was stabilized for 64 weeks. The M3 patients did not show any immunological or clinical response. In 11 patients, the biodistribution of 111In-labeled AM was investigated. There was no clear evidence that AM injected intradermally or subcutaneously left the site of injection. After injection into a lymph vessel of the foot region, scintigraphs showed five to ten popliteal and inguinocrural lymph nodes. This appeared to be the most efficient way to administer rapidly and safely large amounts of peptide-loaded APC into lymph nodes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lesimple</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><Affiliation>Centre Régional de Lutte Contre le Cancer Eugène Marquis, rue de la Bataille Flandres-Dunkerque, CD 44229, 35042 Rennes, France. lesimple@rennes.fnclcc.fr</Affiliation></Author><Author ValidYN="Y"><LastName>Moisan</LastName><ForeName>Annick</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Carsin</LastName><ForeName>André</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ollivier</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mousseau</LastName><ForeName>Mireille</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Meunier</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Leberre</LastName><ForeName>Claudine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Collet</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Quillien</LastName><ForeName>Véronique</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Drenou</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lefeuvre-Plesse</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chevrant-Breton</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Toujas</LastName><ForeName>Louis</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2003</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Cancer Immunol Immunother</MedlineTA><NlmUniqueID>8605732</NlmUniqueID><ISSNLinking>0340-7004</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antigens, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>CCR7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>HLA-A2 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>MAGEA3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, CCR7</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Chemokine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83869-56-1</RegistryNumber><NameOfSubstance>Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antigens, Neoplasm</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">HLA-A2 Antigen</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Injections</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Intradermal Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Macrophages</DescriptorName><QualifierName MajorTopicYN="N">drug effects</QualifierName><QualifierName MajorTopicYN="Y">physiology</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Melanoma</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, CCR7</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Chemokine</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>Aug</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>Feb</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2003</Year><Month>Apr</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12690521</ArticleId><ArticleId IdType="doi">10.1007/s00262-003-0390-y</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003293 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003293 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12690521
|texte= Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12690521" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |